Efficacy of lipid profiles in prediction of coronary disease☆
References (20)
- et al.
Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin
J Am Coll Cardiol
(1986) - et al.
Coronary heart disease is not preventable by population interventions
Lancet
(1988) Lowering blood cholesterol to prevent heart disease
JAMA
(1985)Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults
Arch Int Med
(1988)Treatment of hypertriglyceridemia
JAMA
(1984)The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease
JAMA
(1984)- et al.
Helsinki Heart Study Primary Prevention Trial with gemfibrozil in middle-aged men with dyslipidemia
N Engl J Med
(1987) - et al.
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous by-pass grafts
JAMA
(1987) - et al.
Effects of therapy with Cholestyramine on progression of coronary atherosclerosis. Results of the NHLBI Type II Coronary Intervention Study
Circulation
(1984) - et al.
Regression of coronary artery disease as a result of apolipoprotein B
N Engl J Med
(1990)
Cited by (116)
A mechanism-based operational definition and classification of hypercholesterolemia
2022, Journal of Clinical LipidologyCitation Excerpt :We have chosen the threshold levels of LDLc and non-HDLc in the present document (130 and 160 mg/dL, or 3.4 and 4.1 mmol/L, respectively) in part because NCEP ATP III has already defined them in the past as being predictive of ASCVD risk.15 The knowledge of LDLc and non-HDLc already have proven clinical utility; e.g. they demonstrate excellent sensitivity in screening of hypercholesterolemia of genetic origin in adults;14 and the threshold level chosen for either elevated LDLc or non-HDLc divides the population into lower- and higher-risk groups associated with an approximate doubling of ASCVD risk.16,17 However, the threshold levels of LDLc and non-HDLc chosen to define primary hypercholesterolemia are usually higher (see below), and are situated within the lower range of levels for most genetic hypercholesterolemias in adults.14,18–20
High-density lipoproteins: A consensus statement from the National Lipid Association
2013, Journal of Clinical LipidologyCitation Excerpt :This ratio has been found to be one of the most powerful lipid measures for predicting CVD events.42,43 Comparing age-adjusted fifth with first quintile lipid CVD risk ratios for the individual lipids and their ratios, it is evident that the total-C/HDL-C and LDL-C/HDL-C ratios are stronger predictors of CHD than the individual lipids that comprise them (Table 2).44 However, knowledge of the individual (total-C and HDL-C) components is important, and in risk assessment and treatment recommendations both are examined as 2 separate, but related, risk factors.45–47
Usefulness of lipoprotein ratios in assessing carotid atherosclerosis in Japanese type 2 diabetic patients
2011, AtherosclerosisCitation Excerpt :Among these factors, dyslipidemia may play a primary role in the development of atherosclerotic vascular disease and subsequent death due to the disease [1]. Since many observational and interventional studies have demonstrated that low-density lipoprotein (LDL) is the primary atherogenic lipoprotein [2–4] and that high-density lipoprotein (HDL) is the predominant anti-atherosclerotic lipoprotein [5], measurements of total cholesterol (TC), LDL cholesterol (LDL-C), and HDL cholesterol (HDL-C) are widely recommended [1,6]. However, there is a growing evidence suggesting that non-HDL cholesterol (non-HDL-C), defined as the difference between TC and HDL-C to include all atherogenic apoB-containing lipoproteins, is a better tool for assessing the risk of CVD [7–11].
Statins in the perioperative period: Take it or leave it?
2009, Praticien en Anesthesie ReanimationPrevention of atherosclerosis with low-density lipoprotein cholesterol lowering-lipoprotein changes and interactions: the SANDS study
2009, Journal of Clinical Lipidology
- ☆
Supported by The National Heart, Lung and Blood Institute Grant numbers NIH-N01-HV-92922 and NIH-N01-HV-52971; The Charles A. Dana Foundation; Merck, Sharp and Dohme; Pfizer, and Imperial Chemical Industries.